Physician profile
Eva Barlowe
NPI 1700592706
$3,601.01
in general payments reported to CMS, 2019-2025
20 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,455 · 2024: $871 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.74 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $513.91 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $460.27 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $398.30 | 2023-2025 | Caplyta |
| Abbvie INC. | $377.14 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $339.89 | 2023-2025 | Ingrezza |
| Almatica Pharma LLC | $297.62 | 2023-2025 | Loreev Xr |
| Lundbeck LLC | $189.87 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $161.77 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $159.82 | 2023-2025 | Spravato |
| Axsome Therapeutics, INC. | $146.55 | 2023-2025 | Auvelity |
| Alkermes, INC. | $105.54 | 2023-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $87.23 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $79.16 | 2023-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $66.11 | 2024-2025 | Trintellix |
| Corium, LLC | $48.84 | 2023-2025 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $48.17 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Neos Therapeutics, LP | $44.97 | 2023-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $27.59 | 2024 | |
| Luye Pharma (USA) LTD. | $24.48 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $23.78 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Barlowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.